Enfortumab vedotin (Padcev®)

Assessment Status Awaiting response from Applicant
HTA ID 22024
Drug Enfortumab vedotin
Brand Padcev®
Indication As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (la/mUC) who have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor
Assessment Process
Rapid review commissioned 22/04/2022
Rapid review completed 18/05/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of enfortumab vedotin (Padcev®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 27/05/2022
Pre-submission consultation with Applicant 19/07/2022
Full submission received from Applicant 23/11/2022
Preliminary review sent to Applicant 16/03/2023